by In2Pharma | Jan 13, 2025 | News
Belgium For companies that sell food supplements in one of Belgium’s nine German-speaking municipalities, there has been a positive development on the file regarding the use of German. Minister Clarinval has decided to extend the tolerance period for derogations...
by In2Pharma | Jan 8, 2025 | News
Belgium Companies with a GDP-certificate with validity date end December 2024, should have received – addressed to their RP – a communication from the FAMHP with regard to the GDP-certificate expiring in December 2024. In parallel, the below...
by In2Pharma | Jan 7, 2025 | News
The Netherlands Starting January 1, 2025, several changes to the KOAG KAG rates and procedure have taken effect. Updates rates To align the rates with the workload associated with each type of material, the pricing structure has been re-evaluated. Most rates remain...
by In2Pharma | Dec 27, 2024 | News
The Netherlands Patients with severe conditions who have no access to approved medicinal products can receive treatment through a Compassionate Use Program (CUP). The Medicines Evaluation Board (MEB) has published new policy guidelines for the implementation of these...
by In2Pharma | Dec 27, 2024 | News
Europe An update to Delegated Regulation (EU) 2024/1701, which amends Regulation (EC) No 1234/2008, has been published and will come into effect on 1 January 2025. This regulation addresses the examination of variations to the terms of marketing authorisations for...
